MMRF FastFacts

A monthly e-newsletter

Dear Friends,

Our team just recently returned from the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) more inspired than ever by the progress being made in multiple myeloma and the research programs we are driving. Most exciting were data presented by our industry partners on five trials of promising next-generation treatments conducted in collaboration with our clinical research network, the Multiple Myeloma Research Consortium (MMRC). Learn more about these and other data from ASCO by checking out our **blog**.

All the best,

Kathy Giusti

P.S. We value your feedback – **please let us know what you think.**

Breaking News

MMRF Reports from ASCO

The MMRF is pleased to report exciting new data presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 3-7 in Chicago. Read our **blog** and watch our **webcast**, chaired by Rafael Fonseca, MD, and G. David Roodman, MD, PhD, for highlights.

Share:

New Data from MMRC Clinical Trials Presented at ASCO Annual Meeting

MMRC industry partners—Onyx Pharmaceuticals, Bristol-Myers Squibb, Abbott, and Novartis Pharmaceuticals Corporation—presented data at ASCO from five studies conducted in collaboration with the MMRC to investigate some of today's most promising new therapies, including **carfilzomib**, **elotuzumab**, **panobinostat**, and **pomalidomide**.

MMRC Announces-Data-Presentations >
Onyx Pharmaceuticals Announces
Updated Pivotal Carfilzomib Phase 2b Data >

Share:

Velcade-Based Combinations Yield High Response Rates

Two studies presented at ASCO showed promising response rates in heavily pre-treated patients with relapsed or refractory multiple myeloma who were treated with Velcade-based combinations. Both were early phase trials that investigated the safety and efficacy of Velcade in combination with two novel agents - LY2127399, a human monoclonal antibody and panobinostat (also a MMRF treatment study), an HDAC inhibitor, studied through the MMRC. **More >**

Share:

Zometa Reduces Skeletal-Related Events, Boosts Survival in Multiple Myeloma Patients

Treatment with Zometa® significantly reduced skeletal-related events in patients with multiple myeloma, according to data presented at ASCO. When combined with chemotherapy, Zometa also improved overall survival compared with clodronate. **More >**

Share:

MMRC, Astellas Partner to Launch Phase 1 Clinical Trial

The MMRC and Astellas Pharma announced a joint collaboration on a Phase I clinical trial of OSI-906, an IGF-1R inhibitor, in patients with relapsed myeloma. The trial, which will be conducted through the MMRC, will evaluate OSI-906 as both a single agent and in combination with Velcade. Partial funding for this trial is made possible by the donor-supported MMRF Clinical Fund, which enables the MMRF to invest in the development of industry-owned compounds whose development in multiple myeloma is delayed due to matters of prioritization. **More >**

Share:

MMRF Founder Featured in Harvard Business Review

MMRF founder and CEO Kathy Giusti, a Harvard Business School alumna, was profiled in the June issue of the Harvard Business Review. The journal chronicles how Kathy used her business and science background to transition from a successful pharmaceutical executive to found and lead the MMRF and MMRC. Giusti also delivered the commencement address at Harvard Business School's 2011 class day - **watch it here**. **More >**

Share:

Stevie Wonder to be Honored at 15th Annual MMRF Fall Gala

The MMRF will honor the legendary Stevie Wonder with the MMRF Spirit of Hope Award at its 15th annual MMRF Fall Gala, on Oct. 29, 2011, in Greenwich, Connecticut. Save the date! **More >**

Share:

MMRF Laugh for Life: New York Raises More Than $620,000 for Myeloma Research

The Ninth Annual MMRF Life for Life: New York raised more than $620,000 for multiple myeloma research. Special thanks to Cat Greenleaf, host of NBC's "Talk Stoop with Cat Greenleaf," comedian John Pinette, and New York supporters who made the evening such an amazing success! **More >**

Share:

Research Updates

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy **More >**

Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, Cascavilla N, Montefusco V, Lupo B, Liberati AM, Cripps C, Rossini F, Passera R, Patriarca F, Cafro AM, Omedè P, Carella AM, Peccatori J, Catalano L, Caravita T, Musto P, Petrucci MT, Boccadoro M, Palumbo A
Leukemia. 2011 Jun 3. [Epub ahead of print]

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial **More >**

Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A
Am J Hematol. 2011 Apr 18. doi: 10.1002/ajh.22053. [Epub ahead of print]

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma **More >**

Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desalah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R
Am J Hematol. 2011 Apr 7. doi: 10.1002/ajh.22048. [Epub ahead of print]

Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome **More >**

Nivison-Smith I, Dodds AJ, Doocey R, Ganly P, Gibson J, Ma DD, Simpson JM, Szer J, Bradstock KF
Leuk Lymphoma. 2011 May 27. [Epub ahead of print]

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance **More >**

Ruschak AM, Slassi M, Kay LE, Schimmer AD
J Natl Cancer Inst. 2011 May 23. [Epub ahead of print]

Characterizing and Predicting Pathologic Spine Fractures in Myeloma Patients With FDG PET/CT and MR Imaging **More >**

Mulligan M, Chrinden A, Karchevsky M
Cancer Invest. 2011 Jun;29(5):370-6.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial **More >**

Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Meitzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine DL, Kelley SL, Kaminski MS, Anderson KC, Richardson PG
Blood. 2011 May 23. [Epub ahead of print]

Carfilzomib: a novel second-generation proteasome inhibitor **More >**

Khan ML, Stewart AK
Future Oncol. 2011 May;7(5):607-12.

Multiple myeloma. Progress is being made. **More >**

Mayo Clin Health Lett. 2011 Mar;29(3):4-5.

Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy **More >**

Kyle RA
Mayo Clin Proc. 2011 May;86(5):419-20.

Clinical Trials

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma **More >**

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST) **More >**

A Phase I/II Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma **More >**

Expert Insights

MMRF Clinical Insights

Learn about myeloma treatment options. Join us at our free patient education programs this fall in Atlanta, Boston and Chicago. For more information and to register, visit our **Clinical Insights Webpage**.

Register Now

Share:

CME-ACCREDITED WEBCASTS

Updates from the 13th International Myeloma Workshop

Updates from the 47th ASCO Annual Meeting

FOR PATIENTS AND CAREGIVERS

Highlights from the 13th International Myeloma Workshop archived teleconference

Get Involved

MMRF Fall Gala

The 15th Annual MMRF Fall Gala will be held Sat., Oct. 29, at the Hyatt Regency Greenwich in Old Greenwich, CT. **Deborah Norville**, Emmy Award winning broadcast journalist, will serve as Mistress of Ceremonies and the legendary singer and songwriter **Stevie Wonder** will be honored with the MMRF Spirit of Hope Award. For more information, email **mmrf@benefitoffice.org**.

Purchase Tickets

Share:

MMRF Race for Research Fall Series

Join us for the MMRF Race for Research Fall Series in Atlanta, Boston, Chicago, Philadelphia, Twin Cities and Washington DC. For more information, email **races@themmrf.org**.

Register Now

Share:

MMRF Endurance Events

Participate in a marathon, half marathon, triathlon, cycling event or shorter distance race to support the MMRF. Registration is now open! For more information **email us**.

Register Now

Share:

MMRF Store

Father's Day is almost here. Give a gift to the men in your life that also benefits myeloma research. Make a purchase from the **MMRF Store** today.

Shop Now

Share:

Start a Fundraiser

Your favorite activities can help support the MMRF! Use a concert, sporting event, wine tasting, or letter writing campaign to raise funds to help develop next-generation treatments. For more information, please contact **events@themmrf.org**.

Plan an Event

Share:

MMRF Tribute Pages

Creating a personalized Tribute Page is a thoughtful and meaningful way to provide you and others with the opportunity to honor your friend or family member's journey with multiple myeloma.

Create Now

Share: